Scholar Rock Holding Corporation $SRRK Shares Sold by TD Asset Management Inc

TD Asset Management Inc lowered its stake in Scholar Rock Holding Corporation (NASDAQ:SRRK) by 9.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 281,444 shares of the company’s stock after selling 30,954 shares during the quarter. TD Asset Management Inc’s holdings in Scholar Rock were worth $12,398,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of SRRK. AQR Capital Management LLC lifted its holdings in Scholar Rock by 609.3% in the first quarter. AQR Capital Management LLC now owns 57,294 shares of the company’s stock worth $1,842,000 after purchasing an additional 49,217 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Scholar Rock by 12.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,046 shares of the company’s stock worth $1,709,000 after purchasing an additional 5,831 shares during the period. Millennium Management LLC lifted its holdings in Scholar Rock by 37.4% in the first quarter. Millennium Management LLC now owns 200,255 shares of the company’s stock worth $6,438,000 after purchasing an additional 54,555 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Scholar Rock by 25.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 169,825 shares of the company’s stock worth $5,460,000 after acquiring an additional 34,594 shares in the last quarter. Finally, Strs Ohio bought a new stake in Scholar Rock in the first quarter worth about $77,000. Institutional investors and hedge funds own 91.08% of the company’s stock.

Scholar Rock Price Performance

NASDAQ SRRK opened at $43.80 on Tuesday. The stock’s 50-day moving average price is $47.99 and its two-hundred day moving average price is $45.72. The company has a current ratio of 8.64, a quick ratio of 8.64 and a debt-to-equity ratio of 0.71. The company has a market cap of $5.25 billion, a PE ratio of -12.20 and a beta of 0.69. Scholar Rock Holding Corporation has a 1 year low of $27.07 and a 1 year high of $52.19.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.01). During the same period in the previous year, the business posted ($0.67) earnings per share. On average, analysts predict that Scholar Rock Holding Corporation will post -3.23 EPS for the current year.

Wall Street Analysts Forecast Growth

SRRK has been the topic of several research reports. Piper Sandler boosted their price target on shares of Scholar Rock from $51.00 to $58.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 4th. Citigroup boosted their price target on shares of Scholar Rock from $55.00 to $58.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Raymond James Financial reiterated a “strong-buy” rating on shares of Scholar Rock in a research report on Tuesday, March 3rd. Canaccord Genuity Group initiated coverage on shares of Scholar Rock in a research report on Monday, April 20th. They issued a “buy” rating and a $62.00 price target on the stock. Finally, JPMorgan Chase & Co. boosted their price target on shares of Scholar Rock from $47.00 to $50.00 and gave the stock an “overweight” rating in a research report on Monday, March 16th. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Scholar Rock has an average rating of “Buy” and an average target price of $56.00.

Insider Buying and Selling

In other Scholar Rock news, insider Akshay Vaishnaw sold 12,246 shares of the business’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $49.57, for a total transaction of $607,034.22. Following the sale, the insider owned 630,542 shares in the company, valued at approximately $31,255,966.94. The trade was a 1.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Keith Woods sold 10,220 shares of the business’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $49.57, for a total value of $506,605.40. Following the sale, the chief operating officer owned 620,055 shares in the company, valued at approximately $30,736,126.35. The trade was a 1.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 63,491 shares of company stock worth $3,147,249 in the last quarter. 13.30% of the stock is currently owned by corporate insiders.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).